RU2470643C2 - Способы применения антагонистов вазопрессина с антрациклиновыми химиотерапевтическими средствами для снижения кардиотоксичности и/или улучшения выживания - Google Patents

Способы применения антагонистов вазопрессина с антрациклиновыми химиотерапевтическими средствами для снижения кардиотоксичности и/или улучшения выживания Download PDF

Info

Publication number
RU2470643C2
RU2470643C2 RU2009146376/15A RU2009146376A RU2470643C2 RU 2470643 C2 RU2470643 C2 RU 2470643C2 RU 2009146376/15 A RU2009146376/15 A RU 2009146376/15A RU 2009146376 A RU2009146376 A RU 2009146376A RU 2470643 C2 RU2470643 C2 RU 2470643C2
Authority
RU
Russia
Prior art keywords
vasopressin
doxorubicin
tolvaptan
antagonist
anthracycline
Prior art date
Application number
RU2009146376/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2009146376A (ru
Inventor
Юнгэ ЛЮ
Дзунити КАМБАЯСИ
Original Assignee
Оцука Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оцука Фармасьютикал Ко., Лтд. filed Critical Оцука Фармасьютикал Ко., Лтд.
Publication of RU2009146376A publication Critical patent/RU2009146376A/ru
Application granted granted Critical
Publication of RU2470643C2 publication Critical patent/RU2470643C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2009146376/15A 2007-05-15 2008-05-12 Способы применения антагонистов вазопрессина с антрациклиновыми химиотерапевтическими средствами для снижения кардиотоксичности и/или улучшения выживания RU2470643C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93808907P 2007-05-15 2007-05-15
US60/938,089 2007-05-15
PCT/US2008/063374 WO2008144269A2 (en) 2007-05-15 2008-05-12 Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival

Publications (2)

Publication Number Publication Date
RU2009146376A RU2009146376A (ru) 2011-06-20
RU2470643C2 true RU2470643C2 (ru) 2012-12-27

Family

ID=40122254

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009146376/15A RU2470643C2 (ru) 2007-05-15 2008-05-12 Способы применения антагонистов вазопрессина с антрациклиновыми химиотерапевтическими средствами для снижения кардиотоксичности и/или улучшения выживания

Country Status (25)

Country Link
US (1) US8372830B2 (es)
EP (1) EP2146721B1 (es)
KR (1) KR101508797B1 (es)
CN (2) CN103550233A (es)
AR (1) AR066544A1 (es)
AU (1) AU2008254273B2 (es)
BR (1) BRPI0811134A2 (es)
CA (1) CA2685186A1 (es)
CO (1) CO6280574A2 (es)
CY (1) CY1114163T1 (es)
DK (1) DK2146721T3 (es)
ES (1) ES2421639T3 (es)
HK (2) HK1138772A1 (es)
HR (1) HRP20130920T1 (es)
IL (1) IL202094A (es)
MX (1) MX2009012164A (es)
MY (1) MY150682A (es)
NZ (1) NZ581126A (es)
PL (1) PL2146721T3 (es)
PT (1) PT2146721E (es)
RU (1) RU2470643C2 (es)
SI (1) SI2146721T1 (es)
TW (1) TWI428131B (es)
UA (1) UA99914C2 (es)
WO (1) WO2008144269A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2211906A2 (en) * 2007-11-07 2010-08-04 Janssen Pharmaceutica, N.V. Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists
WO2013176955A1 (en) * 2012-05-21 2013-11-28 The General Hospital Corporation Cardioprotective compounds, their use with chemotherapy, and methods for identifying them
US20150238502A1 (en) * 2012-10-18 2015-08-27 University Of South Florida Compositions and Methods for Treating Stroke
EP2970311A4 (en) 2013-03-14 2016-11-23 Brigham & Womens Hospital BMP INHIBITORS AND METHODS OF USE
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
US10172911B2 (en) 2013-10-01 2019-01-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of modulating erythropoiesis with arginine vasopressin receptor 1B molecules
WO2016011019A1 (en) 2014-07-15 2016-01-21 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting bmp
CN116063580A (zh) 2016-01-04 2023-05-05 艾得佩索拉公司 肽类似物
WO2017139154A1 (en) * 2016-02-09 2017-08-17 Adepthera Llc Dosing and use of long-acting clr/ramp agonists
WO2018226875A2 (en) * 2017-06-07 2018-12-13 University Of Kansas Methods and medicaments for the treatment of renal cell carcinoma
US20190153059A1 (en) 2017-06-30 2019-05-23 Adepthera Llc Peptide analogs
TWI737974B (zh) 2018-04-09 2021-09-01 美商標徑製藥公司 用於治療增生性失調的劑量方案

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744455A (en) * 1988-01-27 1998-04-28 New York University Reduction of anthracycline-induced cardiotoxicity
RU99101118A (ru) * 1996-06-24 2001-01-10 Нюкомед Имагинг АС Снижение кардиотоксичности противоопухолевого агента путем использования соединения марганца

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US574455A (en) * 1897-01-05 Switch-lock
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744455A (en) * 1988-01-27 1998-04-28 New York University Reduction of anthracycline-induced cardiotoxicity
RU99101118A (ru) * 1996-06-24 2001-01-10 Нюкомед Имагинг АС Снижение кардиотоксичности противоопухолевого агента путем использования соединения марганца

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
(56)US 5744455 А, 28.04.1998. *
GHEORGHIADE M. et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003 Jun 3; 107(21):2690-6. *
WEXLERLH. Amelioration of chemotherapy induced cardiotoxicity. 1998. Seminars in Oncology. Vol.25. No. 4. suppl.10. P.86-92. *
ОРЛОВА Р.В. Пути снижения кардиотоксичности антрациклиновых антибиотиков при комбинированной химиотерапии диссеминированного рака молочной железы. - Актуальные вопросы онкологии, 1996, с.218-219. *
ОРЛОВА Р.В. Пути снижения кардиотоксичности антрациклиновых антибиотиков при комбинированной химиотерапии диссеминированного рака молочной железы. - Актуальные вопросы онкологии, 1996, с.218-219. WEXLERLH. Amelioration of chemotherapy induced cardiotoxicity. 1998. Seminars in Oncology. Vol.25. № 4. suppl.10. P.86-92. GHEORGHIADE M. et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003 Jun 3; 107(21):2690-6. *

Also Published As

Publication number Publication date
HK1176318A1 (en) 2013-07-26
CA2685186A1 (en) 2008-11-27
HK1138772A1 (en) 2010-09-03
US8372830B2 (en) 2013-02-12
TW200916104A (en) 2009-04-16
ES2421639T3 (es) 2013-09-04
KR101508797B1 (ko) 2015-04-06
SI2146721T1 (sl) 2013-10-30
KR20100019439A (ko) 2010-02-18
CO6280574A2 (es) 2011-05-20
EP2146721A4 (en) 2010-08-25
NZ581126A (en) 2012-04-27
BRPI0811134A2 (pt) 2014-09-30
RU2009146376A (ru) 2011-06-20
AU2008254273B2 (en) 2013-03-28
CN101808517A (zh) 2010-08-18
MX2009012164A (es) 2009-12-09
CN103550233A (zh) 2014-02-05
AU2008254273A1 (en) 2008-11-27
WO2008144269A2 (en) 2008-11-27
EP2146721A2 (en) 2010-01-27
IL202094A0 (en) 2010-06-16
AR066544A1 (es) 2009-08-26
UA99914C2 (ru) 2012-10-25
CY1114163T1 (el) 2016-08-31
TWI428131B (zh) 2014-03-01
DK2146721T3 (da) 2013-07-22
WO2008144269A3 (en) 2010-01-21
US20100249104A1 (en) 2010-09-30
MY150682A (en) 2014-02-28
PL2146721T3 (pl) 2013-12-31
HRP20130920T1 (hr) 2013-11-08
IL202094A (en) 2015-06-30
EP2146721B1 (en) 2013-07-10
PT2146721E (pt) 2013-07-18

Similar Documents

Publication Publication Date Title
RU2470643C2 (ru) Способы применения антагонистов вазопрессина с антрациклиновыми химиотерапевтическими средствами для снижения кардиотоксичности и/или улучшения выживания
US7749993B2 (en) Method for treating severe heart failure and medicament therefor
RU2640485C2 (ru) Комбинированное лечение рака
US8642661B2 (en) Pharmaceutical combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonists
US9522129B2 (en) Pharmaceutical Combination
JP2017522281A (ja) キノリン誘導体による軟部組織肉腫の治療方法と用途、及び軟部組織肉腫治療するための薬用組成物
JP2008502622A (ja) プロリンまたはその誘導体および抗腫瘍抗体からなる抗癌組成物
US8778897B2 (en) Method of treatment using α-1-adrenergic agonist compounds
TW589184B (en) Pharmaceutical composition for preventing or reversing diabetic cardiomyopathy
Waagstein et al. Clinical results with prenalterol in patients with heart failure
WO2013119910A1 (en) Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder
EP1408977B1 (en) A combination therapy for the treatment of heart failure
EP1062948A1 (en) Remedies for cardiac dilastolic disorders
MX2013013124A (es) Combinaciones de trospio y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
WO2024220839A1 (en) Methods of treating hepatic-only metastatic uveal melanoma

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160513